BPI21-004: A Qualitative Study Describing Oncology Practitioners’ Approaches to First-Line (1L) Treatment of Metastatic Urothelial Cancer (mUC) in the United States

Authors: Petros Grivas MD, PhD¹, Meaghan Roach MPH², Vivek Pawar PhD³, Caroline Huber MPH², Suepattra May-Slatter MPH, PhD², Isha Desai MPH², Jane Chang MPH⁴, and Murtuza Bharmal PhD⁵

View More View Less

¹ University of Washington; Seattle Cancer Care Alliance, Fred Hutchinson Cancer Research Center, Seattle, WA
| ² PRECISIONheor, New York, NY
| ³ EMD Serono Research & Development Institute, Inc., Billerica, Massachusetts; an affiliate of Merck KGaA, Darmstadt, Germany
| ⁴ Pfizer Inc, New York, NY
| ⁵ EMD Serono, Inc., Rockland, MA, USA; an affiliate of Merck KGaA, Darmstadt, Germany

Restricted access

All currencies in US Dollar

Corresponding Author: Murtuza Bharmal, PhD

Share Link